Medical Device and Diagnostic Industry: Biodesix Makes the Case for VeriStrat Through New Study

Posted on

“The Biodesix VeriStrat test received an extra dose of validation last week through a 1,048-patient study published in the Oncologist. The study demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer (NSCLC).”


Read the full story.